Search

Your search keyword '"Krishnamurthy, Jairam"' showing total 146 results
Start Over Author "Krishnamurthy, Jairam"
146 results on '"Krishnamurthy, Jairam"'

4. Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

5. Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

6. Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

7. Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

8. Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

9. Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2024
Full Text
View/download PDF

10. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Calfa, Carmen J., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Burness, Monika L., Gogineni, Keerthi, Rohatgi, Nitin, Al Baghdadi, Tareq, Conlin, Alison, Gaba, Anu, Hamid, Omid, Krishnamurthy, Jairam, Gavini, Naga Jyothi, Gold, Philip J., Rodon, Jordi, Rueter, Jens, Thota, Ramya, Grantham, Gina N., and Hinshaw, Dominique C.

Subjects
SUNITINIB, CANCER patients, BREAST cancer, METASTATIC breast cancer, DRUG target
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results from cohorts of patients with metastatic breast cancer (BC) with FGFR1 and FGFR2 alterations treated with sunitinib are reported. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Forty patients with BC with FGFR1 (N = 30; amplification only n = 26, mutation only n = 1, both n = 3) or FGFR2 (N = 10; amplification only n = 2, mutation only n = 6, both n = 2) alterations were enrolled. Three patients in the FGFR1 cohort were not evaluable for efficacy; all patients in the FGFR2 cohort were evaluable. For the FGFR1 cohort, two patients with partial response and four with SD16+ were observed for DC and OR rates of 27% (90% CI, 13 to 100) and 7% (95% CI, 1 to 24), respectively. The null hypothesis of 15% DC rate was not rejected (P =.169). No patients achieved DC in the FGFR2 cohort (P = 1.00). Thirteen of the 40 total patients across both cohorts had at least one grade 3-4 adverse event or serious adverse event at least possibly related to sunitinib. CONCLUSION: Sunitinib did not meet prespecified criteria to declare a signal of antitumor activity in patients with BC with either FGFR1 or FGFR2 alterations. Other treatments and clinical trials should be considered for these patient populations. Sunitinib did not demonstrate antitumor activity in patients with FGFR1-/2-amplified or -mutated breast cancer. @ASCO #TAPUR [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Methods S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 2 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2023
Full Text
View/download PDF

16. Data from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, primary, Zheng, Tiantian, primary, Dai, Chao, primary, Dong, Xiaoxi, primary, Tan, Lu, primary, Suresh, Rama, primary, Ademuyiwa, Foluso O., primary, Rigden, Caron, primary, Rearden, Timothy P., primary, Clifton, Katherine, primary, Weilbaecher, Katherine, primary, Frith, Ashley, primary, Tandra, Pavan K., primary, Summa, Tracy, primary, Haas, Brittney, primary, Thomas, Shana, primary, Hernandez-Aya, Leonel F., primary, Peterson, Lindsay L., primary, Wang, Xiaohong, primary, Luo, Shujun J., primary, Zhou, Kemin, primary, Du, Pan, primary, Jia, Shidong, primary, King, Bonnie L., primary, Krishnamurthy, Jairam, primary, and Ma, Cynthia X., primary

Published
2023
Full Text
View/download PDF

18. Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain

Author

Krishnan, Mridula, Krishnamurthy, Jairam, and Shonka, Nicole

Subjects
Clinical trials -- Analysis, Atezolizumab -- Dosage and administration, Medical research, Breast cancer -- Drug therapy -- Prognosis, Pertuzumab, Lapatinib, Cancer metastasis, Health
Abstract

Brain metastasis is a poor prognostic factor in breast cancer progression, and traditional treatment options have shown minimal response with overall low median survival rates. The incidence of brain metastasis has been increasing despite and, in part, due to advancements in treatment as a result of prolongation of survival. Targeted therapy such anti-HER2 agents have a lower efficacy in this setting compared to metastases elsewhere; however, novel therapies are emerging in this regard. In this comprehensive review, we discuss risk per subtype, special considerations for therapy selection, current focal and systemic treatments, and recent advancements and potential future targets for success. We present our treatment paradigm and multidisciplinary approach to brain metastases arising from breast cancer based on the available evidence, incorporating molecular characteristics., Introduction Breast cancer has the second highest incidence of brain metastasis among all malignancies. There are few systemic therapies that penetrate the blood-brain barrier (BBB).[1,2] Brain metastasis carries a very [...]

Published
2019

19. Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, additional, Zheng, Tiantian, additional, Dai, Chao, additional, Dong, Xiaoxi, additional, Tan, Lu, additional, Suresh, Rama, additional, Ademuyiwa, Foluso O., additional, Rigden, Caron, additional, Rearden, Timothy P., additional, Clifton, Katherine, additional, Weilbaecher, Katherine, additional, Frith, Ashley, additional, Tandra, Pavankumar K., additional, Summa, Tracy, additional, Haas, Brittney, additional, Thomas, Shana, additional, Hernandez-Aya, Leonel F., additional, Peterson, Lindsay L., additional, Wang, Xiaohong, additional, Luo, Shujun J., additional, Zhou, Kemin, additional, Du, Pan, additional, Jia, Shidong, additional, King, Bonnie L., additional, Krishnamurthy, Jairam, additional, and Ma, Cynthia X., additional

Published
2023
Full Text
View/download PDF

20. 70. Assessment of circulating tumor DNA tumor mutational burden to define resistance in HR+ HER2- metastatic breast cancer

Author

Davis, Andrew A., primary, Luo, Jingqin, additional, Zheng, Tiantian, additional, Dong, Xiaoxi, additional, Tan, Lu, additional, Wang, Amy, additional, Suresh, Rama, additional, Ademuyiwa, Foluso, additional, Rigden, Caron, additional, Rearden, Timothy, additional, Clifton, Katherine, additional, Weilbaecher, Katherine, additional, Frith, Ashley, additional, Tandra, Pavan K., additional, Summa, Tracy, additional, Haas, Britney, additional, Thomas, Shana, additional, Hernandez-Aya, Leonel, additional, Peterson, Lindsay, additional, Dai, Chao, additional, King, Bonnie L., additional, Du, Pan, additional, Jia, Shidong, additional, Krishnamurthy, Jairam, additional, and Ma, Cynthia X., additional

Published
2022
Full Text
View/download PDF

21. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Author

Gradishar, William J., primary, Moran, Meena S., additional, Abraham, Jame, additional, Aft, Rebecca, additional, Agnese, Doreen, additional, Allison, Kimberly H., additional, Anderson, Bethany, additional, Burstein, Harold J., additional, Chew, Helen, additional, Dang, Chau, additional, Elias, Anthony D., additional, Giordano, Sharon H., additional, Goetz, Matthew P., additional, Goldstein, Lori J., additional, Hurvitz, Sara A., additional, Isakoff, Steven J., additional, Jankowitz, Rachel C., additional, Javid, Sara H., additional, Krishnamurthy, Jairam, additional, Leitch, Marilyn, additional, Lyons, Janice, additional, Mortimer, Joanne, additional, Patel, Sameer A., additional, Pierce, Lori J., additional, Rosenberger, Laura H., additional, Rugo, Hope S., additional, Sitapati, Amy, additional, Smith, Karen Lisa, additional, Smith, Mary Lou, additional, Soliman, Hatem, additional, Stringer-Reasor, Erica M., additional, Telli, Melinda L., additional, Ward, John H., additional, Wisinski, Kari B., additional, Young, Jessica S., additional, Burns, Jennifer, additional, and Kumar, Rashmi, additional

Published
2022
Full Text
View/download PDF

22. Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6i)

Author

Davis, Andrew, primary, Luo, Jingqin, additional, Zheng, Tiantian, additional, Tan, Lu, additional, Wang, Amy, additional, Suresh, Rama, additional, Ademuyiwa, Foluso, additional, Rigden, Caron, additional, Rearden, Timothy, additional, Clifton, Katherine, additional, Weilbaecher, Katherine, additional, Frith, Ashley, additional, Tandra, Pavan K, additional, Summa, Tracy, additional, Haas, Brittney, additional, Thomas, Shana, additional, Hernandez-Aya, Leonel, additional, Peterson, Lindsay, additional, Luo, Shujun, additional, King, Bonnie L, additional, Jia, Shidong, additional, Yu, Jianjun, additional, Du, Pan, additional, Krishnamurthy, Jairam, additional, Ma, Cynthia X, additional, and Dai, C, additional

Published
2022
Full Text
View/download PDF

23. Abstract OT1-17-02: A phase II study of pembrolizumab plus fulvestrant in hormone receptor positive, HER-2 negative advanced/metastatic breast cancer patients

Author

Chan, Nancy, primary, Moore, Dirk, additional, Tandra, Pavankumar, additional, Rana, Jatin, additional, Omene, Coral, additional, George, Mridula, additional, Krishnamurthy, Jairam, additional, Desai, Shruti, additional, Patel, Nayana, additional, Wang, Yue, additional, Bicomong, Marc, additional, Tan, Xiao-wei, additional, Hirshfield, Kim, additional, Ganesan, Shridar, additional, and Toppmeyer, Deborah, additional

Published
2022
Full Text
View/download PDF

24. Contributors

Author

Adesoye, Taiwo, Aebi, Stefan, Aizer, Ayal, Allweis, Tanir M., Arnold, Alicia Huff, Ashfaq, Raheela, Barrio, Andrea V., Bazan, Jose G., Bedrosian, Isabelle, Berkowitz, Alyssa, Bland, Kirby I., Aydi, Zeynep B., Braunstein, Lior Z., Brufsky, Adam, Cahlon, Oren, Carlson, Kjirsten A., Cass, Samuel, Cathcart-Rake, Elizabeth, Caudle, Abigail, Chen, Zhengshan, Chen, Chien, Childs, Daniel S., Chung, Alice, Cody, Hiram S., III, Coleman, Robert, Copeland, Edward M., III, Cox, Solange E., Cox, Dawn M., Czyz, Rebecca, David, Bre Ana, Degnim, Amy C., Dhakal, Ajay, Dietz, Jill R., Esgueva, Antonio J., Euhus, David M., Farr, Deborah E., Fayanju, Oluwadamilola M., Freedman, Gary M., Gallagher, Kristalyn K., Garvey, Patrick Bryan, Gass, Jennifer S., Geletzke, Abby K., Gemignani, Mary L., Giuliano, Armando E., Goldman, Kara N., Golshan, Mehra, Goodman, Chelain R., Gradishar, William J., Greenberg, Caprice C., Grobmyer, Stephen R., Grubstein, Ahuva, Gutnik, Lily, Harris, Eleanor E., Howard, Frederick M., Hunt, Kelly K., Jhawar, Sachin R., Jungheim, Emily S., Kaklamani, Virginia, Kalliath, Naomi J., Karuturi, Meghan S., Kass, Rena B., Khan, Seema A., Khan, Maryam I., Khan, Sadia, Suzanne Klimberg, V., Korourian, Soheila, Krishnamurthy, Jairam, Kuerer, Henry M., Kumarapeli, Asangi R., Kumbla, Pallavi A., Kumthekar, Priya, Lathrop, Kate I., Lee, Anne E., Marilyn Leitch, A., Liang, Diana, Lin, Nancy U., Linda Bi, Wenya, Lippe, Caroline E., Lu, Janice, Lustberg, Maryam, Ma, Emily, Ma, Yanling, Della Makower, Mallory, Melissa Anne, Mancino, Anne Thompson, Massoll, Nicole, Matalkah, Ahmad M., Matar, Regina, Mathew, Aju, McCormick, Beryl, McGuire, Kandace P., Mehra, Karishma, Mendez, Jane E., Menes, Tehillah, Merajver, Sofia D., Mhatre, Priya V., Mitchell, Sunny D., Morikawa, Aki, Muesse, Jason L., Nanda, Rita, Okoro, Stanley, O'Regan, Ruth M., Osipo, Clodia, Pariser, Ashley, Pastoriza, Jessica, Patel, Vijay, Pernas, Sonia, Piltin, Mara A., Pisano, Courtney E., Podoll, Mirna B., Post, Ginell R., Prati, Raquel, Press, Michael F., Pusztai, Lajos, Racz, Jennifer, Rivere, Amy E., Robinson, Angelica S., Rosenbloom, Arlan L., Rosso, Kelly J., Rozenblit, Mariya, Rubio, Isabel T., Ruddy, Kathryn J., Sanders, Melinda E., Sanft, Tara, Savalia, Nirav B., Schuetz, Steven J., Sener, Stephen F., Shah, Ami N., Shahpar, Samman, Shalin, Sara C., Siddiq, Namrah, Silverstein, Melvin J., Simpson, Ashley, Singhal, Dhruv, Smith, Benjamin D., Smith, Karen Lisa, Spanheimer, Philip M., Sparano, Joseph A., Spiguel, Lisa R.P., Stearns, Vered, Steliga, Matthew A., Sun, Susie X., Tarantino, Paolo, Tolaney, Sara M., De La Torre, Jorge I., Tsai, Jacqueline, Valente, Stephanie A., Sorice-Virk, Sarah, Vogel, Victor G., Wapnir, Irene L., Weiser, Roi, Yaney, Alex, Yellala, Amulya, and Zanfagnin, Valentina

Published
2024
Full Text
View/download PDF

26. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

Author

Xi, Jing, Oza, Aabha, Thomas, Shana, Naughton, Michael, Ademuyiwa, Foluso, Weilbaecher, Katherine, Suresh, Rama, Bose, Ron, Cherian, Mathew, Hernandez-Aya, Leonel, Frith, Ashley, Peterson, Lindsay, Luo, Jingqin, Krishnamurthy, Jairam, and Ma, Cynthia X.

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Pyridines, medicine.medical_treatment, Anastrozole, Antineoplastic Agents, Breast Neoplasms, Kaplan-Meier Estimate, Palbociclib, Article, Piperazines, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Exemestane, Internal medicine, Biomarkers, Tumor, Humans, Medicine, Molecular Targeted Therapy, Practice Patterns, Physicians', Protein Kinase Inhibitors, Aged, Retrospective Studies, Fulvestrant, business.industry, Letrozole, Middle Aged, Prognosis, medicine.disease, Combined Modality Therapy, Metastatic breast cancer, Treatment Outcome, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Retreatment, Disease Progression, Female, Hormone therapy, business, Follow-Up Studies, medicine.drug, Eribulin
Abstract

Background:Cyclin-dependent kinase (CDK) 4/6 inhibitors are now the standard of care for hormone receptor–positive (HR+), HER2-negative (HER–) metastatic breast cancer (MBC). However, guidelines are lacking regarding their optimal sequencing with other available agents. This study examines physician practice patterns and treatment outcomes of palbociclib and subsequent therapies in a real-world setting.Methods:A retrospective chart review was conducted for consecutive patients with MBC who received palbociclib between February 2015 and August 2017 at the Alvin J. Siteman Cancer Center. Kaplan-Meier method was used to generate time-to-event curves and estimate median progression-free survival (mPFS). Log-rank test was used to compare differences.Results:A total of 200 patients, with a median age of 59.4 years and a follow-up of 19.5 months, were included. Palbociclib was most frequently combined with letrozole (73.5%), followed by fulvestrant (25%), anastrozole (1%), and tamoxifen (0.5%). Most patients received palbociclib in the endocrine-resistant setting (n=42, n=50, and n=108 in the first-, second-, and subsequent-line settings, respectively), and the fraction of patients receiving palbociclib as first- or second-line therapy increased in recent months (P=.0428). mPFS was 20.7, 12.8, and 4.0 months with palbociclib administered in the first-, second-, and subsequent-line settings, respectively (PP=.04). mPFS with chemotherapy (n=70) was not reached, 4.7, and 4.1 months after first-, second-, and subsequent-line palbociclib, respectively (P=.56).Conclusions:Palbociclib is effective for HR+/HER2– MBC in real-world practice. Hormone therapy alone or in combination with targeted agents remains an effective option after palbociclib progression.

Published
2019

27. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Author

Gradishar, William J., primary, Moran, Meena S., additional, Abraham, Jame, additional, Aft, Rebecca, additional, Agnese, Doreen, additional, Allison, Kimberly H., additional, Blair, Sarah L., additional, Burstein, Harold J., additional, Dang, Chau, additional, Elias, Anthony D., additional, Giordano, Sharon H., additional, Goetz, Matthew P., additional, Goldstein, Lori J., additional, Hurvitz, Sara A., additional, Isakoff, Steven J., additional, Jankowitz, Rachel C., additional, Javid, Sara H., additional, Krishnamurthy, Jairam, additional, Leitch, Marilyn, additional, Lyons, Janice, additional, Matro, Jennifer, additional, Mayer, Ingrid A., additional, Mortimer, Joanne, additional, O'Regan, Ruth M., additional, Patel, Sameer A., additional, Pierce, Lori J., additional, Rugo, Hope S., additional, Sitapati, Amy, additional, Smith, Karen Lisa, additional, Smith, Mary Lou, additional, Soliman, Hatem, additional, Stringer-Reasor, Erica M., additional, Telli, Melinda L., additional, Ward, John H., additional, Wisinski, Kari B., additional, Young, Jessica S., additional, Burns, Jennifer L., additional, and Kumar, Rashmi, additional

Published
2021
Full Text
View/download PDF

28. Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response

Author

Krishnamurthy, Jairam, primary, Luo, Jingqin, additional, Suresh, Rama, additional, Ademuyiwa, Foluso, additional, Rigden, Caron, additional, Reardon, Timothy, additional, Clifton, Katherine, additional, Weilbaecher, Katherine, additional, Frith, Ashley, additional, Roshal, Anna, additional, Tandra, Pavan, additional, Cherian, Mathew, additional, Summa, Tracy, additional, Thomas, Shana, additional, Hernandez-Aya, Leonel, additional, Bergqvist, Mattias, additional, Peterson, Lindsay, additional, and Ma, Cynthia X, additional

Published
2021
Full Text
View/download PDF

31. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Gradishar, William J., primary, Anderson, Benjamin O., additional, Abraham, Jame, additional, Aft, Rebecca, additional, Agnese, Doreen, additional, Allison, Kimberly H., additional, Blair, Sarah L., additional, Burstein, Harold J., additional, Dang, Chau, additional, Elias, Anthony D., additional, Giordano, Sharon H., additional, Goetz, Matthew P., additional, Goldstein, Lori J., additional, Isakoff, Steven J., additional, Krishnamurthy, Jairam, additional, Lyons, Janice, additional, Marcom, P. Kelly, additional, Matro, Jennifer, additional, Mayer, Ingrid A., additional, Moran, Meena S., additional, Mortimer, Joanne, additional, O'Regan, Ruth M., additional, Patel, Sameer A., additional, Pierce, Lori J., additional, Rugo, Hope S., additional, Sitapati, Amy, additional, Smith, Karen Lisa, additional, Smith, Mary Lou, additional, Soliman, Hatem, additional, Stringer-Reasor, Erica M., additional, Telli, Melinda L., additional, Ward, John H., additional, Young, Jessica S., additional, Burns, Jennifer L., additional, and Kumar, Rashmi, additional

Published
2020
Full Text
View/download PDF

32. Abstract P1-19-13: A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo

Author

Krishnamurthy, Jairam, primary, Luo, Jingqin, additional, Ademuyiwa, Foluso, additional, Suresh, Rama, additional, Rigden, Caron, additional, Reardon, Timothy, additional, Weilbaecher, Katherine, additional, Frith, Ashley, additional, Roshal, Anna, additional, Tandra, Pavan, additional, Cherian, Mathew, additional, Summa, Tracy, additional, Thomas, Shana, additional, Hernandez-Aya, Leonel, additional, Peterson, Lindsay, additional, and Ma, Cynthia, additional

Published
2020
Full Text
View/download PDF

49. Paraneoplastic Manifestations of Lymphoproliferative Neoplasms.

Author

Tandra, Pavankumar, Kallam, Avyakta, Guduru, Mounika, Bendi, Venkata Sunil, Krishnamurthy, Jairam, and Bierman, Philip

Subjects
PARANEOPLASTIC syndromes, LYMPHOPROLIFERATIVE disorders, TUMOR classification, PATHOLOGICAL physiology, CANCER chemotherapy, HORMONE therapy, ADRENOCORTICAL hormones
Abstract

Paraneoplastic syndromes, although rare, have been associated with lymphoproliferative disorders. Hodgkin's lymphoma (HL) is the most common lymphoid neoplasm known to cause paraneoplastic syndromes. These syndromes can often be the earliest manifestation of the underlying malignancy, and treating the underlying lymphoma can cure the paraneoplastic disease. Paraneoplastic diseases reported in lymphoid malignancies can be broadly classified into hematological, neurological, and dermatological syndromes based on the organ systems that are predominantly involved. In addition, renal and hepatobiliary involvement has also been reported. The pathogenesis of the hematological paraneoplastic conditions primarily involves the production of autoantibodies by the neoplastic lymphocytes, which then subsequently leads to cytopenias. Cytoses are a result of cytokine produced by the neoplasms. The administration of corticosteroids along with chemotherapy for the underlying malignancy is the treatment of choice. Neurological paraneoplastic phenomena have been reported in both HL and non-Hodgkin's lymphoma (NHL). They are thought to be secondary to an immune-related process that is triggered by the underlying process. Both the central and the peripheral nervous systems can be affected. Often, treatment of the underlying malignancy with chemotherapy can result in reversal of the paraneoplastic syndrome. In peripheral neuropathies, muscle relaxants and analgesics are often used for symptomatic relief. Dermatological manifestations, pemphigus vulgaris in particular, often precedes the malignancy. Renal and hepatobiliary manifestations, although rare, are also associated with lymphomas. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

50. Effect of Palliative Care Services on the Aggressiveness of End-of-Life Care in the Veteran's Affairs Cancer Population

Author

Gonsalves, Wilson I., primary, Tashi, Tsewang, additional, Krishnamurthy, Jairam, additional, Davies, Tracy, additional, Ortman, Stephanie, additional, Thota, Ramya, additional, Aldoss, Ibrahim, additional, Ganta, Ashwin, additional, Kalaiah, Mudappa, additional, Didwaniya, Neha, additional, Eberle, Catherine, additional, Ganti, Apar K., additional, Silberstein, Peter T., additional, and Subbiah, Shanmuga, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results